Innovative Molecular/Cellular Analysis Technologies for Cancer Research
IMAT funding opportunities are designed to encourage applications from individuals and groups interested in developing novel technologies suitable for the molecular analysis of cancers and their host environment in support of basic, clinical, and epidemiological research.
Innovative Biospecimen Science Technologies for Cancer Research
Innovative and emerging technologies may be developed for cancer-relevant biospecimen science to measure and/or control pre-analytical variations in the collection, processing, handling, and storage of cancer-relevant biospecimens or their derivatives to improve their quality and utility in cancer research.
Application and Use of Transformative Emerging Technologies in Cancer Research
Emerging Technologies funding opportunities are intended to support projects to evaluate the usefulness of emerging technologies in appropriate biological contexts in order to assess reproducibility and produce preliminary data toward a biological or clinical question.
Integrating of IMAT Technologies into active NCI grant awards.
The purpose of these RFAs is based on the recognition that R21 and R33 awards are effective for advancing technology development research to the point of robust analytical validation of a new technology within a generic cancer-relevant context of use, but more work is often required to achieve the “reduction to practice” of a new capability sufficient to encourage end-users from a targeted field to feel confident that they can incorporate that technology into their own research efforts.